Ikena Oncology Inc IKNA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/21/24 EDT
1.39quote price arrow up+0.01 (+0.64%)
Volume
2,718
Close
1.38UNCH (UNCH)
Volume
49,394
52 week range
1.02 - 7.38
Loading...
  • Open1.41
  • Day High1.42
  • Day Low1.32
  • Prev Close1.38
  • 52 Week High7.38
  • 52 Week High Date06/16/23
  • 52 Week Low1.02
  • 52 Week Low Date11/09/23

Key Stats

  • Market Cap66.596M
  • Shares Out48.26M
  • 10 Day Average Volume0.19M
  • Dividend-
  • Dividend Yield-
  • Beta0.39
  • YTD % Change-29.95

KEY STATS

  • Open1.41
  • Day High1.42
  • Day Low1.32
  • Prev Close1.38
  • 52 Week High7.38
  • 52 Week High Date06/16/23
  • 52 Week Low1.02
  • 52 Week Low Date11/09/23
  • Market Cap66.596M
  • Shares Out48.26M
  • 10 Day Average Volume0.19M
  • Dividend-
  • Dividend Yield-
  • Beta0.39
  • YTD % Change-29.95

RATIOS/PROFITABILITY

  • EPS (TTM)-1.58
  • P/E (TTM)-0.88
  • Fwd P/E (NTM)-0.95
  • EBITDA (TTM)-74.537M
  • ROE (TTM)-48.28%
  • Revenue (TTM)3.848M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,821.54%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ikena Oncology Inc

 

Content From Our Affiliates

Profile

MORE
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted...
Owen Hughes Jr.
Independent Chairman of the Board
Mark Manfredi Ph.D.
President, Chief Executive Officer, Director
Jotin Marango
Chief Financial Officer, Head of Corporate Development
Address
50 Northern Ave.
Boston, MA
02210
United States

Top Peers

SYMBOLLASTCHG%CHG
MNOV
MediciNova Inc
1.39UNCHUNCH
BTAI
BioXcel Therapeutics Inc
2.01UNCHUNCH
CVM
CEL-SCI Corp
1.31UNCHUNCH
LABP
Landos Biopharma Inc
22.30UNCHUNCH
VNRX
VolitionRX Ltd
0.7201UNCHUNCH